| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
|
Jafarnejad, Mohammad
|
|
2019
|
21 |
5 |
p. 1-14
|
artikel
|
| 2 |
A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance
|
Kavita, Uma
|
|
2019
|
21 |
5 |
p. 1-13
|
artikel
|
| 3 |
Anthocyanin Delphinidin Prevents Neoplastic Transformation of Mouse Skin JB6 P+ Cells: Epigenetic Re-activation of Nrf2-ARE Pathway
|
Kuo, Hsiao-Chen Dina
|
|
2019
|
21 |
5 |
p. 1-10
|
artikel
|
| 4 |
Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis
|
Gorovits, Boris
|
|
2019
|
21 |
5 |
p. 1-7
|
artikel
|
| 5 |
A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
|
Brussee, Janneke M.
|
|
2019
|
21 |
5 |
p. 1-11
|
artikel
|
| 6 |
A Tangeretin Derivative Inhibits the Growth of Human Prostate Cancer LNCaP Cells by Epigenetically Restoring p21 Gene Expression and Inhibiting Cancer Stem-like Cell Proliferation
|
Wei, Guor-Jien
|
|
2019
|
21 |
5 |
p. 1-12
|
artikel
|
| 7 |
A Tangeretin Derivative Inhibits the Growth of Human Prostate Cancer LNCaP Cells by Epigenetically Restoring p21 Gene Expression and Inhibiting Cancer Stem-like Cell Proliferation
|
Wei, Guor-Jien
|
|
|
21 |
5 |
|
artikel
|
| 8 |
Cellular Uptake and Distribution of Gemini Surfactant Nanoparticles Used as Gene Delivery Agents
|
Jin, Wei
|
|
2019
|
21 |
5 |
p. 1-11
|
artikel
|
| 9 |
Characterization and Quantification of an Fc-FGF21 Fusion Protein in Rat Serum Using Immunoaffinity LC-MS
|
Li, Fengping
|
|
2019
|
21 |
5 |
p. 1-10
|
artikel
|
| 10 |
Compensated Hydroxyl Radical Protein Footprinting Measures Buffer and Excipient Effects on Conformation and Aggregation in an Adalimumab Biosimilar
|
Misra, Sandeep K.
|
|
2019
|
21 |
5 |
p. 1-9
|
artikel
|
| 11 |
Correction to: Metabolic Profile of 3-Acetyl-11-Keto-β-Boswellic Acid and 11-Keto-β-Boswellic Acid in Human Preparations In Vitro, Species Differences, and Bioactivity Variation
|
Cui, Yonglei
|
|
2019
|
21 |
5 |
p. 1
|
artikel
|
| 12 |
Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies
|
Zhang, Ting-Ting
|
|
2019
|
21 |
5 |
p. 1-11
|
artikel
|
| 13 |
Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1
|
Hamuro, Lora
|
|
2019
|
21 |
5 |
p. 1-12
|
artikel
|
| 14 |
Evaluation of Assumptions Underpinning Pharmacometric Models
|
Ooi, Qing-Xi
|
|
2019
|
21 |
5 |
p. 1-11
|
artikel
|
| 15 |
Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction
|
Kapetas, Asha J
|
|
2019
|
21 |
5 |
p. 1-11
|
artikel
|
| 16 |
Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies
|
Treyer, Andrea
|
|
2019
|
21 |
5 |
p. 1-10
|
artikel
|
| 17 |
Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective
|
Bi, Youwei
|
|
2019
|
21 |
5 |
p. 1-6
|
artikel
|
| 18 |
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats
|
Yu, Ruihong
|
|
2019
|
21 |
5 |
p. 1-9
|
artikel
|
| 19 |
Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples
|
Li, Cindy Yanfei
|
|
2019
|
21 |
5 |
p. 1-8
|
artikel
|
| 20 |
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models
|
Papathanasiou, Theodoros
|
|
2019
|
21 |
5 |
p. 1-11
|
artikel
|
| 21 |
Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation
|
Ueshima, Satoshi
|
|
2019
|
21 |
5 |
p. 1-9
|
artikel
|
| 22 |
Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift
|
Azadeh, Mitra
|
|
2019
|
21 |
5 |
p. 1-14
|
artikel
|
| 23 |
Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System
|
Martinez, Marilyn N.
|
|
2019
|
21 |
5 |
p. 1-12
|
artikel
|
| 24 |
Reduced Systemic and Brain Exposure with Inhibited Liver Metabolism of Carbamazepine After Its Long-Term Combination Treatment with Piperine for Epilepsy Control in Rats
|
Ren, Tianjing
|
|
2019
|
21 |
5 |
p. 1-16
|
artikel
|
| 25 |
Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
|
Brekkan, Ari
|
|
2019
|
21 |
5 |
p. 1-11
|
artikel
|
| 26 |
TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity
|
Yogurtcu, Osman N.
|
|
2019
|
21 |
5 |
p. 1-12
|
artikel
|
Tijdschrift beschrijving